Clare Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Clare Chen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Christopher S. Gondi
University of Illinois Urbana-Champaign University of Illinois Urbana-Champaign University of Illinois Chicago University of Illinois Chicago University of Illinois Chicago University of Illinois Chicago University of Illinois at Urbana-Champaign University of Illinois Chicago University of Illinois Urbana-Champaign
2 shared publications - Lusine Demirkhanyan
Department of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA
2 shared publications - Ameena Patel
Department of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA
1 shared publication - Andrew W. Browne
Gavin Herbert Eye Institute – Center for Translational Vision Research University of California Irvine Irvine California USA
1 shared publication - Austen Hamilton
Brunson Center for Translational Vision Research, University of California Irvine, Irvine, CA 92697, USA
1 shared publication - Francis Ung
Department of Ophthalmology and Visual Sciences, University of California Irvine, Irvine, CA 92697, USA
1 shared publication
Latest Publications
- Open Access
- 6 February 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (2) , 188
A Novel, Low-Cost, 3D-Printed Motorized Injector for Retinal Sheet Transplantation
Retinal transplantation offers promise for restoring vision in advanced retinal degeneration. However, manual delivery of retinal sheets is often hindered by imprecise placement and collateral tissue damage resulting from instrument instability. We introduce a novel, 3D-printed, motorized retinal sheet injector designed to enhance placement accuracy and minimize tissue injury. The motorized injector features an Arduino-controlled foot pedal with three discrete actuator positions (“Min”, “Mid”, “Max”). When compared via frame-by-frame motion analysis, the motorized system reduced tip variance by approximately threefold over manual methods. In addition, in in vitro gelatin trials, the motorized injector achieved significantly higher placement accuracy versus the manual injector, which suffered from occasional complete misplacements. The novel motorized retinal sheet injector markedly improves stability and placement accuracy relative to manual methods, potentially reducing complications associated with subretinal delivery. Safer subretinal delivery can pave the way for innovative research and advanced treatment for retinal disease.
- 6 February 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (2) , 188
Open AccessA Novel, Low-Cost, 3D-Printed Motorized Injector for Retinal Sheet Transplantation
Retinal transplantation offers promise for restoring vision in advanced retinal degeneration. However, manual delivery of retinal sheets is often hindered by imprecise placement and collateral tissue damage resulting from instrument instability. We introduce a novel, 3D-printed, motorized retinal sheet injector designed to enhance placement accuracy and minimize tissue injury. The motorized injector features an Arduino-controlled foot pedal with three discrete actuator positions (“Min”, “Mid”, “Max”). When compared via frame-by-frame motion analysis, the motorized system reduced tip variance by approximately threefold over manual methods. In addition, in in vitro gelatin trials, the motorized injector achieved significantly higher placement accuracy versus the manual injector, which suffered from occasional complete misplacements. The novel motorized retinal sheet injector markedly improves stability and placement accuracy relative to manual methods, potentially reducing complications associated with subretinal delivery. Safer subretinal delivery can pave the way for innovative research and advanced treatment for retinal disease.
- Open Access
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 406
The Role of Mucins in Cancer and Cancer Progression: A Comprehensive Review
Mucin, a heavily glycosylated glycoprotein, serves an important function in forming protective and immune defense barriers against the exterior environment on epithelial surfaces. While secreted-type mucins are involved in mucous production, transmembrane mucins, which contain O-glycosylated tandem repeats, play a pivotal role in cellular signaling, especially in immune modulation and mediating inflammatory response. However, dysregulation in mucin expressions, such as MUC1, MUC2, MUC4, MUC5AC, and MUC16, have been observed in many cancer cells. More specifically, alterations in the expression and glycosylation of MUC1 have been associated with the upregulation of pathways involving the cell proliferation, angiogenesis, migration, and invasion of cancer cells. With mucin’s extensive involvement in cancer biology, several mucin biomarkers, such as CA125, CA19-9, and CEA, have been utilized as diagnostic and prognostic monitoring biomarkers in ovarian, pancreatic, and colon cancer. Vaccines and antibody therapy against abnormal mucin glycosylation have also been investigated for potential therapy for mucin-related cancers that are resistant to traditional chemotherapy agents. Despite the lack of specificity in mucin biomarkers and challenges in efficient drug delivery systems, the current advancement in mucin-targeted immunotherapy highlighted the pivotal potential in developing therapeutic targets to improve cancer prognosis.
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 406
Open AccessThe Role of Mucins in Cancer and Cancer Progression: A Comprehensive Review
Mucin, a heavily glycosylated glycoprotein, serves an important function in forming protective and immune defense barriers against the exterior environment on epithelial surfaces. While secreted-type mucins are involved in mucous production, transmembrane mucins, which contain O-glycosylated tandem repeats, play a pivotal role in cellular signaling, especially in immune modulation and mediating inflammatory response. However, dysregulation in mucin expressions, such as MUC1, MUC2, MUC4, MUC5AC, and MUC16, have been observed in many cancer cells. More specifically, alterations in the expression and glycosylation of MUC1 have been associated with the upregulation of pathways involving the cell proliferation, angiogenesis, migration, and invasion of cancer cells. With mucin’s extensive involvement in cancer biology, several mucin biomarkers, such as CA125, CA19-9, and CEA, have been utilized as diagnostic and prognostic monitoring biomarkers in ovarian, pancreatic, and colon cancer. Vaccines and antibody therapy against abnormal mucin glycosylation have also been investigated for potential therapy for mucin-related cancers that are resistant to traditional chemotherapy agents. Despite the lack of specificity in mucin biomarkers and challenges in efficient drug delivery systems, the current advancement in mucin-targeted immunotherapy highlighted the pivotal potential in developing therapeutic targets to improve cancer prognosis.
- Open Access
The Multifaceted Role of miR-21 in Pancreatic Cancers
With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among various biomarkers, microRNA-21 (miR-21), a small non-coding RNA, is highly expressed in PDAC. By inhibiting regulatory proteins at the 3′ untranslated regions (UTR), miR-21 holds significant roles in PDAC cell proliferation, epithelial–mesenchymal transition, angiogenesis, as well as cancer invasion, metastasis, and resistance therapy. We conducted a systematic search across major databases for articles on miR-21 and pancreatic cancer mainly published within the last decade, focusing on their diagnostic, prognostic, therapeutic, and biological roles. This rigorous approach ensured a comprehensive review of miR-21’s multifaceted role in pancreatic cancers. In this review, we explore the current understandings and future directions regarding the regulation, diagnostic, prognostic, and therapeutic potential of targeting miR-21 in PDAC. This exhaustive review discusses the involvement of miR-21 in proliferation, epithelial–mesenchymal transition (EMT), apoptosis modulation, angiogenesis, and its role in therapy resistance. Also discussed in the review is the interplay between various molecular pathways that contribute to tumor progression, with specific reference to pancreatic ductal adenocarcinoma.
Open AccessThe Multifaceted Role of miR-21 in Pancreatic Cancers
With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among various biomarkers, microRNA-21 (miR-21), a small non-coding RNA, is highly expressed in PDAC. By inhibiting regulatory proteins at the 3′ untranslated regions (UTR), miR-21 holds significant roles in PDAC cell proliferation, epithelial–mesenchymal transition, angiogenesis, as well as cancer invasion, metastasis, and resistance therapy. We conducted a systematic search across major databases for articles on miR-21 and pancreatic cancer mainly published within the last decade, focusing on their diagnostic, prognostic, therapeutic, and biological roles. This rigorous approach ensured a comprehensive review of miR-21’s multifaceted role in pancreatic cancers. In this review, we explore the current understandings and future directions regarding the regulation, diagnostic, prognostic, and therapeutic potential of targeting miR-21 in PDAC. This exhaustive review discusses the involvement of miR-21 in proliferation, epithelial–mesenchymal transition (EMT), apoptosis modulation, angiogenesis, and its role in therapy resistance. Also discussed in the review is the interplay between various molecular pathways that contribute to tumor progression, with specific reference to pancreatic ductal adenocarcinoma.